AB7 America, Inc France

AB7 Industries  R&D and GMP manufacturing company with unique active ingredient release technology devices with application in the human and the animal health sectors Industry sectors Biotech Therapeutics Area Dermatology
Nutrition and Weight Loss
Orthopedics/Orthopedic Surgery
Rheumatology
Your innovative solution

Technology allows for a large quantity of active ingredient to be stored in a polymer matrix for a constant and slow targeted release. The active polymer is either embedded onto textile supports or on self adhesive multi layer long lasting patches or in particles in suspension in a solution. Products include pain relief devices (active textiles or patches), slimming devices, active foot care, mosquito control devices,...

Which problem are you solving ?

We are able to have products lasting much longer because we can insert a large amount of actives in the device and we control the release kinetic. For instance, istead of having a 8 hour pain relief patch, we can obtain a reusable, washable patch equivalent lasting several weeks.

Target market segments

Rheumatology/ Orthopedics / Dermatology / Slimming / Parasite control

Key value proposition

Long lasting active release / Constant release / Targeted area

Mr Philippe Chelle
Director Export 

ADERLY Invest in Lyon France

Aderly Invest in Lyon is the economic development agency of Lyon - France

Nathalie LAURENT
Inward Investment Manager - Life Sciences 

Airspek - Dietsensor France

Airspek - Dietsensor AIRSPEK will launch DietSensor, the first app with sensors that automates nutrient counting anywhere.

Industry sectors

E_health Therapeutics Area  Nutrition and Weight Loss Our innovative solution  Pioneer in automatic nutrient tracking, DietSensor brings a new level of simplicity and accuracy to diet trackers, helping 1.4B overweight people including 166M americans. It analyses the food with a click of a button, using a micro scale and SCIO, the first molecular sensor that fits in a hand. Problem solved  Counting is a first step toward behavior changes. DietSensor will sign the beginning of a new era of tools dedicated to nutrition tracking and coaching, providing an easy tool to 60% of the American adults who say that they try to track their diet but find declarative apps too inconvenient. Market segments  Overweight / Obesity / Diabetes T1&2 / Wellness & healthy eating Key value proposition
  •  it offers an attractive user friendly meal logging experience, avoiding manual search in a database for most of the foods: the scanning user experience takes up to 10 times less clicks to log a food than a manual self declarative input method /
  • spectrometry makes possible accurate analysis of homogeneous food and beverage, taking into account specific cooking and additive ingredient

 

  • the food database and its models will respond accurately on any homogeneous food, even on home made dishes and beverages that do not have a nutritional label /

 

  • DietSensor gives a lot of feedback on food quality and quantity while logging food, making possible immediate behavior changes before eating
REMY BONNASSE
CEO 

ALZPROTECT France

AlzProtect  We develop innovative drugs for the treatment of Neurodegeneration Industry sectors Biotech Therapeutics Area CNS-Neurology
Your innovative solution

We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its nadditional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will nter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP.

Which problem are you solving ?

AZP2006 is developed for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Progressive Supranuclear Palsy.

Target market segments

Alzheimer's disease, Progressive supranuclear palsy, Frontotemporal dementia, Parkinson's disease

Key value proposition

Innovative mode of action/ first-in-class candidate drug/ clinical phase / Orphan status

Philippe VERWAERDE
CEO 

AMA France

AMA, 1 in 10 companies certified "Glass Partner" by Google worldwide, provides mobile and hands-free tele-expertise solutions on smart glasses, mainly in the medical fields. Industry sectors E_health Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dermatology
Gastroenterology / Hepatology
Orthopedics/Orthopedic Surgery
Pediatrics/Neonatology
Your innovative solution


Hands-free, mobile audio-video connection on smart glasses through a HIPAA exchange platform allowing the physician to communicate with the patient and nurse, permitting synchronous tele-consultations. Doctors can take pictures remotely, select areas within the photo to highlight, comment on and transfer to the nurse and patient file.

Which problem are you solving ?

-TELEMEDICINE: AMA's solution brings healthcare expertise to patients, eliminating geographical constraints and improving quality care and patient comfort. - FINANCIAL challenges: reduces transport, hospitalisation costs and time consumption. - EMERGENCY: fast intervention, doubt removal, orientation to best-fitting hospital - E-LEARNING and mentoring: Live and personalised advice and guidance during training/interventions

Target market segments

Emergency 1 / Ambulances 2 / Nursing homes 3 / E-training 4

Key value proposition

Mobility 1 / Hands-free 2 / Videoconferencing (audio - video exchanges) 3 / Efficient (cost and time saving) 4

Contacts:

  • Jean-François DENIS, VP Sales
  • Anne-Fleur ANDRLE, Business Development US

Jean Francois DENIS
VP sales 

AMABIOTICS France

AMABIOTICS Amabiotics is a biopharmaceutical company developing innovative microbiome medicines to fight neurodegenerative diseases Industry sectors BioPharma Therapeutics Area CNS-Neurology
Rare Disease
Your innovative solution

AMABIOTICS analyse metabolic interplays between humans and its microbial associated communities. AMABIOTICS discovered novel actions of natural chemical compounds provided by the microbiome that the host cannot synthesize by itself. Our pipeline of products candidates is led by AMA-101 as a potential first-in-class therapy for Parkinson disease.

Which problem are you solving ?

We address the major issue of preventing mitochondrial dysfunction

Target market segments

1 - Neurodegenerative disease / 2 - Obesity / 3 - Tissue regeneration

Key value proposition

Original and specific mode of action / Crosses the blood-brain barrier / Co-evolution with our organism (low risk of adverse side effect).

Patrice GARNIER
CEO 

Axenis France

YOUR INNOVATIVE SOLUTION:

AXENIS business model is based on the following three ideas :

-Central focus on humanized mouse models and their applications;

-Feed the flow of in-licensed new models and innovations in order to generate the richest possible catalogue of humanized models and pre-clinical studies and accumulate latest models and

related knowledge

-Offer pre-clinical studies to the biopharma industry.

 

WHICH PROBLEM ARE YOU SOLVING?

-Human immuno-profiling for drug discovery and validation;

-Searching for and validating predictive biomarkers of disease progression or resolution (infection, autoimmunity, tumor control…);development/Validation of vaccine, biologicals, small molecules, adjuvants and mAb treatments;

 

TARGET PARTNERS:

Partners/Licensing of immunodeficient mice :

Ø  PDX models/Sell

Ø  US/Asia/India/Europa

Ø  Co-development of new combine models (Liver/Tumor/Muscle..)

 

KEY VALUE PROPOSITION:

It will specialize in bringing the newest validated models to its clients and exploiting these models through in-house experimental studies. The vision of the founders is to make AXENIS a world-wide leading service company in humanized models.

Website:
www.axenis.fr
Dr Erwan Corcuff
CEO 

B CELL DESIGN France

B Cell Design promotes a new approach of mucosal immunotherapies. The innovation is based on a technology platform to generate a large number of drug and vaccine candidates in infectious diseases and oncology.

The preferential tropism of class A isotype for mucosal compartments is the key in treatment of infectious diseases and mucosal cancers (gut, lung) strategies.  Its high resistance (under its secretory form) through the entire digestive tracts, allow an oral administration of anti-cancer immunotherapy. B CELL DESIGN develops a new concept of therapeutic IgA and secretory IgA for anti-colorectal cancer therapy and medical imaging of early-stage metastasis. To target AIDS, B Cell Design develops an alternative vaccine approach for a mucosal induction of a neutralizing response, at the gate of entrance of the virus.

Based on an innovative platform of humanized transgenic mice models, B CELL DESIGN offers a complete panel of specific monoclonal antibodies, hIgG1, hIgA1, hIgA2, SIgA1, hIgM and hIgE. The main issue in the diagnostic industry is to solve the problem of supply in specific human sera, as positive controls and calibrators for their diagnostic kits. Plus, for some diseases, patients developed a combined immune response, requiring testing various isotypes. B CELL DESIGN offers secure solutions to overcome supplying restraints. Working with monoclonal antibodies offers a perfect reproducibility of antibodies affinity, allows keeping quality track of all components of the kit, and ensures a complete safety for users because of a non-human cellular manufacturing system.

 

OBJECTIVES :

B CELL DESIGN is seeking for partners to pursue the development of our drug candidates and to  initiate new projects based on our technological platform.

Armelle CUVILLIER
Chairman, C.S.O 

BBRC-Aminogram France

BBRC-Aminogram BBRC- Aminogram is the French & European specialist in mobile and connected Bio- Impedance Analysis devices. Industry sectors E health Therapeutics Area Cardiology / Vascular Diseases
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Oncology
Pulmonary/Respiratory Diseases
Rare Disease
Rheumatology
Your innovative solution

As a part of our advanced concept and system combining mobile hardware with sensor, smarts of software engines capabilities and personalized dashboard; our exclusive & patented BIA measurement & analysis offers a direct valuation of body composition, hydration and nutrition status at one glance.

Which problem are you solving ?

Our unique 

Target market segments

Health/weight management/Sport/Seniors/

Key value proposition

Connected Device & cloud based engine & storage technology/ The only one in this range of product to deliver instantly full body composition analysis/ Accurate & reliable / Highly personalizable and flexible

Dominique Grillet
Manager directeur 

Bertin Pharma France

BERTIN PHARMA Bertin Pharma, a specialty CRO offering DRUG DELIVERY SYSTEMS solutions from NCE to OTC in a life cycle management oriented mind Industry sectors BioPharma Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology

Your innovative solution

Bertin Pharma recently integrates one of the most outstanding GMP facilities in Europe specifically dedicated to the Pharmaceutical development of OTC. A large panel of original Drug Delivery Systems particularly suitable to fit the OTC needs with optimized sensorial attributes are available. Among them Dualtab

Which problem are you solving ?

DUALTAB

Target market segments

Ethics (NCEs & Biologics), OTC, Generic plus 

Key value proposition

Quick local symptoms relief Dual action quick and long lasting Product design makes dual action visible for patients Robust manufacturing process and low industrial cost price

Luc Grislain
Co-founder